TARSONS · NSE
Tarsons Products Limited
₹303.4
-0.10% (-₹0.3)
Prev. close
₹303.7
Volume
1,00,811
Delivery %
16.6%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “LKP Research recommends buying Tarsons Products with a target price of ₹453. The call is based on the company's strong m…” | LKP Securities AnalysisLKP Securities | Tarsons Products Ltd | MISS | |
| “LKP Research recommends buying Tarson Products with a target price of ₹600. The call is based on their analysis, implyin…” | LKP Securities AnalysisLKP Securities | Tarson Products Ltd | PENDING |
Fundamentals
About Tarsons Products Limited
Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally. The company offers assay plates, biohazard and safetyware, bioprocessing solutions, bottles and carboys, boxes and racks, cell culture ware, centrifuge ware, clamps and stands, clinical and microbiology products, cryoware, desiccators, tubings and connectors, filtration products, general labware, genomics and PCR consumables, laboratory equipment, laboratory utilities, liquid handling consumables, liquid handling reusables, magnetic stirrer bars, PP storage plates, sampling aids, vials and tubes, and volumetric reusables. Its products are used in molecular biology, cell culture, genomics, proteomics, and immunology. Tarsons Products Limited was incorporated in 1983 and is headquartered in Kolkata, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Sanjive Sehgal
Headquarters
Kolkata
Employees
1,108
Website
tarsons.comExchange
View on NSE ↗Key stats
Market cap
₹1,655.25 Cr
P/E ratio (TTM)
148.9
Dividend yield
0.00%
EPS (TTM)
₹2.09
Beta (1Y · daily vs NIFTY 50)
1.15
Beta (5Y · monthly vs NIFTY 50)
1.48
Shares float
1.05 Cr
EPS · quarter ended Jun 2026
₹-0.27
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹300.79 Cr | ₹281.36 Cr | ₹296.39 Cr | ₹392.41 Cr | ₹422.51 Cr | |
EBITDA | — | ₹161.17 Cr | ₹141.62 Cr | ₹111.29 Cr | ₹126.69 Cr | ₹140.97 Cr |
| — | ₹100.66 Cr | ₹80.71 Cr | ₹42.64 Cr | ₹29.77 Cr | ₹14.32 Cr | |
Diluted EPS | — | ₹19.46 | ₹15.17 | ₹8.01 | ₹5.6 | ₹2.69 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹295.95 Cr | ₹544.23 Cr | ₹725.68 Cr | ₹972.18 Cr | ₹1,080.04 Cr | ₹1,185.82 Cr | |
| ₹33.50 Cr | ₹21.67 Cr | ₹110.69 Cr | ₹269.02 Cr | ₹339.17 Cr | ₹392.96 Cr | |
Stockholders' equity | ₹244.34 Cr | ₹489.83 Cr | ₹569.30 Cr | ₹612.86 Cr | ₹630.21 Cr | ₹634.69 Cr |
Fixed assets, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹83.47 Cr | ₹75.60 Cr | ₹102.71 Cr | ₹114.24 Cr | ₹118.48 Cr | |
Investing cash flow | — | ₹-137.95 Cr | ₹-178.55 Cr | ₹-284.95 Cr | ₹-145.49 Cr | ₹-130.37 Cr |
| — | ₹129.58 Cr | ₹84.56 Cr | ₹135.63 Cr | ₹38.95 Cr | ₹8.93 Cr | |
Capital expenditure | — | ₹-131.97 Cr | ₹-189.97 Cr | ₹-184.33 Cr | ₹-151.71 Cr | ₹-125.58 Cr |
End cash position | ₹2.33 Cr | ₹77.44 Cr | ₹59.06 Cr | ₹17.11 Cr | ₹25.13 Cr | ₹23.19 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Nov 21–Dec 21(2Q) | Mar 22–Sep 25(15Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|
| Promoter | 47.30% | 47.31% | 47.30% |
| Public | 52.70% | 52.69% | 52.70% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Tarsons Products Limited | ₹1,548.30 Cr | ₹288.85 | 139.2 | 2.44 | 2.3% | 0.62 | +7.7% | -0.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.